Consistently, high mTOR activity in Grade 4 gliomas has been linked to elevated activity of the cystine–glutamate antiporter xCT [30], which facilitates glutamate secretion and couples metabolic state to excitatory output. This evidence concerns the gene SLC7A11 and central nervous system cancer.